Akari Therapeutics (AKTX) Prepaid Assets (2014 - 2026)
Akari Therapeutics (AKTX) posted quarterly Prepaid Assets of $731000.0 for Q1 2026, up 16.59% year-on-year from $627000.0 in Q1 2025, and up 295.14% on a QoQ basis from $185000.0 in Q4 2025.
Akari Therapeutics (AKTX) Prepaid Assets (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Prepaid Assets for 13 consecutive years, with $731000.0 the latest figure, recorded in Q1 2026.
- Quarterly Prepaid Assets rose 16.59% year-over-year to $731000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $731000.0 (up 16.59% YoY) and the FY2025 annual result came in at $185000.0, down 7.96% from the prior year.
- Prepaid Assets climbed to $731000.0 in Q1 2026 per AKTX's latest filing, from $185000.0 in the prior quarter.
- Over the last five years, Prepaid Assets for AKTX reached as high as $3.1 million in Q2 2022 and fell as low as $185000.0 in Q4 2025.
- A 5-year average of $726987.4 and a median of $465000.0 in 2022 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets jumped 204.79% — and 2023, when it tumbled 79.59%.
- Year by year, Prepaid Assets stood at $465000.0 in 2022, then sank by 35.7% to $299000.0 in 2023, then slumped by 32.78% to $201000.0 in 2024, then slipped by 7.96% to $185000.0 in 2025, then jumped by 295.14% to $731000.0 in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $731000.0, $185000.0, and $349000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 731,000.00 |
| Dec 31, 2025 | 185,000.00 |
| Sep 30, 2025 | 349,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 627,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | 396,000.00 |
| Jun 30, 2024 | 805,000.00 |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | 299,000.00 |
| Jun 30, 2023 | 629,938.00 |
| Dec 31, 2022 | 465,000.00 |
| Jun 30, 2022 | 3.09 Mn |
| Dec 31, 2021 | 2.17 Mn |
| Jun 30, 2021 | 1.01 Mn |
| Dec 31, 2020 | 292,680.00 |
| Sep 30, 2020 | 1.35 Mn |
| Jun 30, 2020 | 1.68 Mn |
| Mar 31, 2020 | 1.83 Mn |
| Dec 31, 2019 | 712,975.00 |